Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
02:22pm, Saturday, 16'th Jan 2021
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
Why Aldeyra Therapeutics Stock Is Jumping Today
11:25am, Thursday, 14'th Jan 2021
The company announced the pricing of a public stock offering.
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
09:36pm, Wednesday, 13'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 13'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
08:00am, Friday, 08'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fir
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, r
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
08:00am, Tuesday, 22'nd Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
05:47am, Sunday, 20'th Dec 2020
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reacti
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
08:00am, Tuesday, 08'th Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
10:19am, Thursday, 05'th Nov 2020
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
08:00am, Wednesday, 04'th Nov 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeutic appro
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
09:22pm, Friday, 30'th Oct 2020
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi ini
Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem
01:27pm, Wednesday, 02'nd Sep 2020
Allergy is a serious rising threat to the new urban lifestyle. Aldeyra’s drug might have the right answer to this problem.
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
06:23am, Monday, 24'th Aug 2020
Two Sample Breakout Stocks for Week 35 with better than 10% short-term upside potential. Now up an average 172.2% YTD.
